Skip to main content
main-content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Cancer 1/2018

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

Zeitschrift:
BMC Cancer > Ausgabe 1/2018
Autoren:
Ming Li, Anqi Li, Shuling Zhou, Yan Xu, Yaoxing Xiao, Rui Bi, Wentao Yang
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12885-017-3916-y) contains supplementary material, which is available to authorized users.

Abstract

Background

Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of the response to anti-PD-L1/anti- programmed cell death 1 (PD-1) therapy in multiple cancers, including triple negative breast cancer(TNBC). The purpose of this study was to investigate whether PD-L1 expression is homogenous in primary tumors(PTs) and synchronous axillary lymph node metastases(LNMs) of TNBC.

Methods

PD-L1 expression was immunohistochemically evaluated in 101 TNBC patients’ PTs and paired LNMs. PD-L1 expression in tumor cells and infiltrating immune cells or node lymphocytes in the PTs and associated LNMs was scored separately and was correlated with patients’ clinical parameters and prognoses.

Results

PD-L1 expression exhibited spatial heterogeneity in both the tumor cells and the infiltrating immune cells or node lymphocytes of PTs and LNMs. The PD-L1 expression levels were significantly higher in the lymphocytes and tumor cells of the LNMs than in the PTs. PD-L1 expression was also more frequent among the LNMs. PD-L1 expression was associated with high grade and more stromal tumor-infiltrating lymphocytes(TILs). Furthermore, the disease-free survival and overall survival were similar between the PT- negative/LNM- positive and PT- positive/LNM- positive patients, both of which exhibited worse disease-free survival(DFS) thanPT -negative/LNM -negative patients.

Conclusions

The differential expression of PD-L1 between the PTs and LNMs suggests that LNMs PD-L1 status may be used to indicate whether PD-1/PD-L1-targeted therapy would be suitable for a node-positive TNBC patient in the future.
Zusatzmaterial
Additional file 1: Figure S1. The validation of PD-L1 antibody. (A) Western blot analysis for PD-L1 using MDA-MB-231 treated with control and PD-L1 targeting siRNAs. (B) Immunoarchitecture of a TNBC lymph nodal metastasis. PD-L1 expression was observed in the lymph node germinal centers, providing an internal positive control for staining. (TIFF 6516 kb)
12885_2017_3916_MOESM1_ESM.tif
Additional file 2: Table S1. Clinicopathological features of the three groups: PT-/LNM-, PT-/LNM+ and PT+/LNM+ (DOCX 19 kb)
12885_2017_3916_MOESM2_ESM.docx
Additional file 3: Figure S2. Kaplan–Meier survival curve for overall survival (OS) according to PD-L1 expression in PTs and LNMs. (TIFF 5345 kb)
12885_2017_3916_MOESM3_ESM.tif
Additional file 4: Table S2. Cox regression analysis of PD-L1 expression and clinicopathological factors predicting OS. (DOCX 15 kb)
12885_2017_3916_MOESM4_ESM.docx
Additional file 5: Table S3. Cox regression analysis of PD-L1 expression and clinicopathological factors predicting DFS. (DOCX 15 kb)
12885_2017_3916_MOESM5_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Cancer 1/2018 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise